ACM
CCCC icon

AlphaCrest Capital Management’s C4 Therapeutics CCCC Stock Holding History

AlphaCrest Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-42,027
Closed -$1.02M – 1257
2022
Q1 		$1.02M Buy
+42,027
New +$1.02M 0.06% 537

Other funds holding CCCC

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AlphaCrest Capital Management's CCCC Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of C4 Therapeutics (CCCC) in Q2 2022, closing a stake of 42,027 shares — an estimated $1.02M sold.

AlphaCrest Capital Management first reported a position in CCCC in Q1 2022 and held it in 1 quarter. The position peaked at $1.02M in Q1 2022. 113 funds tracked by Wall St. Rank hold CCCC as of Q2 2022.

  • AlphaCrest Capital Management reported no remaining C4 Therapeutics position as of Q2 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 42,027 C4 Therapeutics shares in Q2 2022, an estimated $1.02M.
  • AlphaCrest Capital Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 1 quarter.
  • AlphaCrest Capital Management's C4 Therapeutics position peaked at $1.02M in Q1 2022.
  • 113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.